Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacologic Ascorbate With Durvalumab in Non-Small Cell Lung Cancer
NCT06083454Phase 1Terminated
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ascorbic acid and durvalumab in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoint: CD8+ T cells quantified as the percentage of lymphocytes. Started Oct 2023; status: terminated.
02
Drugs
ascorbic aciddurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06083454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083454.